Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma

Teiji Kuzuya, Kaoru Tsuchiya, Keisuke Tanaka, Yuichiro Suzuki, Takahide Hoshioka, Shinji Tamaki, Tomoji Kato, Yutaka Yasui, Tomohiro Tanaka, Takanori Hosokawa, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Masayuki Kurosaki, Yasuhiro Asahina, Namiki Izumi

研究成果: Article査読

1 被引用数 (Scopus)

抄録

We investigated changes in tumor markers before and after sorafenib therapy for advanced hepatocellular carcinoma (HCC). Subjects were 28 patients who began sorafenib therapy. HCC stage was III (n = 5), IVA (n = 10) and IVB (n = 13). AFP, AFP-L3 and PIVKA-II were compared before and at one month after sorafenib administration. While no significant changes were observed for AFP and AFP-L3, PIVKA-II increased significantly following treatment (p<0.001). Similar results were observed for investigation of outcomes based on RECIST criteria (PR, n = 1; SD, n = 18; PD, n = 9), with increases also observed for PR or SD patients. PIVKA-II increased following sorafenib administration regardless of therapeutic effects based on imaging findings. The present results are very interesting from the perspective of the clinical effects of sorafenib.

本文言語English
ページ(範囲)403-404
ページ数2
ジャーナルActa Hepatologica Japonica
51
7
DOI
出版ステータスPublished - 2010
外部発表はい

All Science Journal Classification (ASJC) codes

  • 肝臓学

フィンガープリント

「Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル